Natera, Inc. Annual Report - A Look Back at 2025

This summary breaks down Natera's performance for the year ended December 31, 2025, offering a clear, accessible overview of its annual report. We'll explore the company's operations, financial results, and what these mean for investors.

Natera, trading on the Nasdaq stock exchange under the ticker symbol NTRA, is an established public company. The SEC classifies it as a "large accelerated filer" and a "well-known seasoned issuer," indicating it's a significant company with a consistent track record of meeting its reporting obligations.

Business Overview: Precision Diagnostics for Better Health

Natera specializes in genomic testing, developing and commercializing unique genetic tests that empower patients and healthcare providers to make more informed medical decisions. Its core business spans three key areas:

• Women's Health: Natera offers the Panorama® non-invasive prenatal test (NIPT) for early detection of chromosomal abnormalities and Vistara™ for single-gene disorders.
• Oncology: The company's flagship product, Signatera®, is a personalized molecular residual disease (MRD) test that detects cancer recurrence and monitors treatment effectiveness.
• Organ Health: Prospera® is a cell-free DNA test that assesses the risk of organ transplant rejection.

Financial Performance: Growth Amidst Continued Investment

For the fiscal year ended December 31, 2025, Natera reported significant revenue growth, reaching approximately $1.15 billion. This represents a 28% increase over the previous year, primarily driven by greater adoption and reimbursement for its Signatera and Prospera tests, alongside steady performance in Women's Health.

Despite strong revenue, the company reported a net loss of approximately $250 million for the year. This loss, however, improved from the prior year's $300 million. Natera's ongoing losses reflect substantial investments in research and development (R&D), totaling around $400 million, as well as increased sales and marketing efforts to expand its market presence.

Risk Factors: Key Considerations for Investors

Investing in Natera, like any growth company, involves specific risks:

• Reimbursement Challenges: Natera relies on favorable reimbursement policies from government and private payers for its tests. Changes to these policies could significantly impact revenue.
• Intense Competition: The genomic testing market is highly competitive, with established players and new entrants constantly innovating.
• Regulatory Landscape: Natera operates in a heavily regulated environment. Changes in FDA regulations or other healthcare policies could affect product development and commercialization.
• Litigation: The company is involved in various intellectual property and commercial disputes, which could result in significant costs or adverse outcomes.
• Technological Obsolescence: Rapid advancements in genomic technology mean Natera must continually innovate to remain competitive.
• Ability to Achieve Profitability: The company has a history of net losses and may not achieve or maintain profitability in the future.

Management Discussion & Analysis (MD&A) Highlights: Key Business Progress

The past year brought several important developments:

• Signatera Expansion: Natera significantly expanded Signatera's clinical utility and reimbursement, securing new coverage decisions for colorectal cancer and early-stage breast cancer monitoring. The company also presented compelling new clinical data from multiple studies, demonstrating the test's effectiveness in guiding treatment decisions.
• Prospera Adoption: The Prospera test continued to gain traction, with increased test volumes driven by positive clinical outcomes and growing physician acceptance within the organ transplant community.
• R&D Pipeline: Natera advanced its next-generation oncology pipeline, including progress in early cancer detection research, with initial data expected in late 2026.
• Operational Efficiency: Natera initiated several programs to improve operational efficiency and reduce its cost per test. These initiatives, which include optimizing lab processes and supply chain management, are expected to contribute to future profitability.

Financial Health: Liquidity and Capital Resources

Natera concluded the year with approximately $450 million in cash and cash equivalents, providing liquidity for ongoing operations and strategic initiatives. The company manages its capital structure through a combination of equity and debt financing, including access to a revolving credit facility or convertible notes, to support its growth initiatives and working capital needs. Management believes its current cash position and access to capital are sufficient to meet operational needs and planned investments for the foreseeable future, though future capital raises may be necessary depending on market conditions and strategic opportunities.

Future Outlook: Strategy and Guidance for 2026

Natera's strategy for 2026 centers on three main pillars:

1. Market Leadership in Oncology: Further expanding Signatera's clinical utility and reimbursement across more cancer types and treatment settings, leveraging strong clinical evidence and partnerships.
2. Driving Organ Health Growth: Increasing Prospera's adoption through continued clinical evidence generation, direct sales efforts, and expanding payer coverage.
3. Path to Profitability: While continuing to invest in innovation, the company aims to improve its operational efficiency (operating leverage) and reduce its net loss, targeting a significant reduction in the rate at which it uses cash (cash burn) by the end of 2026. Natera projects revenue growth of 20-25% for the upcoming year, driven by increased test volumes and favorable reimbursement trends.

Competitive Position: Differentiated Offerings in a Dynamic Market

Natera operates in a highly competitive and rapidly evolving genomic testing market. The company maintains its competitive position through several key differentiators:

• Proprietary Technology: Natera's core technology, including its personalized molecular residual disease (MRD) platform for Signatera, offers high sensitivity and specificity, providing a competitive edge.
• Extensive Clinical Evidence: The company consistently invests in generating robust clinical data and publications, which support healthcare providers and payers in adopting its tests.
• Comprehensive Test Menu: Offering a broad portfolio across Women's Health, Oncology, and Organ Health allows Natera to address diverse patient needs and leverage its sales infrastructure.
• Strong Intellectual Property: Natera holds a significant portfolio of patents and intellectual property that protects its technologies and products, creating barriers to entry for competitors.
• Sales and Marketing Reach: The company has established a dedicated and experienced sales force focused on educating clinicians and driving adoption across its key market segments.

While facing competition from established diagnostic companies, academic institutions, and emerging biotech firms, Natera aims to solidify its leadership in personalized oncology and organ transplant monitoring through continuous innovation and market expansion.

In summary, Natera achieved strong revenue growth in 2025, primarily driven by its core oncology and organ health products. While the company continues to invest heavily and operate at a loss, it focuses on expanding market access, advancing its pipeline, and moving towards profitability in the coming years. Investors should weigh the significant growth potential against the inherent risks in the highly dynamic diagnostics industry.